Combination therapy for advanced Merkel cell carcinoma
Part of Cancer, Infections clinical trials.
This study tests a combination of two medicines—an oral therapy (ASTX727) and an immunotherapy (retifanlimab)—for people with advanced Merkel cell carcinoma that has not responded to prior immunotherapy. The goal is to see if this new combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of Merkel cell carcinoma, a rare type of skin cancer.
- Your cancer is advanced (stage III or IV) and cannot be removed with surgery.
- You have already tried an immunotherapy drug (like pembrolizumab or nivolumab) and your cancer did not respond or got worse.
- You have normal organ and bone marrow function, which will be checked with blood tests.
- You have not previously been treated with a hypomethylating agent (like azacitidine or decitabine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a new combination for people with advanced Merkel cell carcinoma (MCC), a rare skin cancer. It combines the immunotherapy drug pembrolizumab with standard chemotherapy (cisplatin or carboplatin plus etoposide). The goal is to see if this combination shrinks or controls the cancer better than chemotherapy alone.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.